SPOTLIGHT -
Drug Shows 10-Month Survival Improvement in Sarcoma
In this video, Dr. Tap discusses a randomized phase Ib/II trial that found that adding olaratumab to doxorubicin dramatically improved survival in patients with advanced soft-tissue sarcoma.
